Live Analyst Rating Changes 22342 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Steve Scala
TD

Steve Scala

TD Cowen
Wall Street Analyst
★★★☆☆
#1134
on 13Foresight · ranked by our own returns
63%
Success Rate
+5.6%
Average Return
24 of 38 calls profitable · -3.9% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 63% of Steve Scala's ratings turned a profit when each position was held for 1 year — averaging +5.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

21 Buy 34 Hold 0 Sell
Steve's Stock Coverage 28 ratings · 2026-08-11
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
GSK
GlaxoSmithKline
 Aug 03, 2026 HOLD Hold
-17.0% avg upside
19 analysts
$70.00
32.13% Upside
 +2.8% ·
ABBV
AbbVie
 Jul 31, 2026 BUY Strong Buy
-3.4% avg upside
46 analysts
$280.00
13.73% Upside
 -1.2% ·
NVS
Novartis
 Jul 27, 2026 HOLD Hold
-14.7% avg upside
24 analysts
$180.00
15.11% Upside
 +0.1% ·
JNJ
Johnson & Johnson
 Jul 13, 2026 BUY Strong Buy
-9.5% avg upside
39 analysts
$300.00
15.69% Upside
 +0.6% ·
ZTS
Zoetis
 Jun 30, 2026 BUY Buy
+62.5% avg upside
23 analysts
$104.00
43.04% Upside
 +4.9% ·
SNY
Sanofi
 Jun 29, 2026 HOLD Strong Buy
+69.8% avg upside
20 analysts
$57.00
31.15% Upside
 +0.1% ·
ELAN
Elanco Animal Health
 Jun 18, 2026 BUY Strong Buy
+41.2% avg upside
18 analysts
$32.00
44.70% Upside
 -8.3% ·
PFE
Pfizer
 May 06, 2026 HOLD Buy
+24.0% avg upside
45 analysts
$30.00
12.13% Upside
 +5.5% ·
GB:AZN
AstraZeneca
 Apr 30, 2026 BUY Strong Buy
+21.5% avg upside
26 analysts
 — -12.3% ·
RHHBY
Roche Holding
 Apr 23, 2026 HOLD Strong Buy
+102.0% avg upside
14 analysts
$67.00
17.02% Upside
 +10.7% ·
LLY
Eli Lilly & Co
 Apr 02, 2026 BUY Strong Buy
-14.0% avg upside
48 analysts
$1250.00
5.48% Upside
 +27.0% ·
MRK
Merck & Company
 Mar 30, 2026 HOLD Strong Buy
-0.9% avg upside
43 analysts
$137.00
6.58% Upside
 +9.7% ·
NVAX
Novavax
 Aug 07, 2025 HOLD Hold
+192.5% avg upside
20 analysts
$8.00
0.61% Upside
 +6.6% ·
BMY
Bristol-Myers Squibb
 Jul 31, 2025 HOLD Buy
-5.9% avg upside
42 analysts
$54.00
16.64% Downside
 +58.0% ·
OGN
Organon
 Apr 22, 2025 HOLD Sell
+9.1% avg upside
9 analysts
$15.00
10.34% Upside
 -17.9% ·
TSE:BHC
Bausch Health Companies
 Feb 21, 2025 HOLD Buy
+555.8% avg upside
29 analysts
$16.74
92.47% Upside
 -19.6% ·
RPRX
Royalty Pharma
 Dec 24, 2024 BUY Strong Buy
-1.2% avg upside
15 analysts
$42.00
26.08% Downside
 +59.5% ·
ANTX
AN2 Therapeutics, Inc.
 Nov 18, 2024 HOLD Buy
+49.0% avg upside
8 analysts
 — +12.0% ·
SPRO
Spero Therapeutics
 Nov 18, 2024 HOLD Buy
+1002.5% avg upside
12 analysts
 — +116.7% ·
CH:NOVN
Novartis AG
 Nov 11, 2024 HOLD Buy
-12.4% avg upside
32 analysts
$109.47
12.87% Downside
 +17.4% ·
NVO
Novo Nordisk
 Apr 30, 2024 BUY Buy
+144.0% avg upside
26 analysts
$155.00
228.04% Upside
 -47.2% ·
GB:0QIU
Novo Nordisk
 Mar 11, 2024 BUY Hold
+35.1% avg upside
29 analysts
$1054.00
245.47% Upside
 · ·
GB:GSK
GlaxoSmithKline
 Nov 30, 2023 HOLD Hold
-0.1% avg upside
25 analysts
$1790.00
6.61% Downside
 -5.9% ·
CH:ROP
Roche Holding AG
 Nov 14, 2022 HOLD Buy
-10.0% avg upside
23 analysts
$367.00
0.56% Downside
 -21.6% ·
FR:SAN
Sanofi
 Jul 21, 2021 HOLD Strong Buy
+29.8% avg upside
30 analysts
$98.00
30.22% Upside
 +15.7% ·
ABUS
Arbutus Biopharma
 Jun 24, 2021 BUY Strong Buy
+92.3% avg upside
15 analysts
 — -13.7% ·
DE:MRK
Merck KGaA
 Dec 10, 2018 HOLD Buy
-4.3% avg upside
33 analysts
$74.43
48.39% Downside
 +8.0% ·
AMGN
Amgen
 Oct 03, 2017 BUY Buy
-23.9% avg upside
57 analysts
$209.00
49.13% Downside
 +13.7% ·
🔒 23 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Steve Scala — Frequently Asked Questions
How accurate are Steve Scala's stock ratings?
Based on the calls 13Foresight could measure, about 63% of Steve's ratings were profitable over a one-year hold, with an average return of +5.6% per rating, or -3.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Steve ranked on 13Foresight?
Steve Scala is currently ranked #1134 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Steve cover?
Steve most recently has ratings on GSK, ABBV, NVS, JNJ, ZTS, SNY, ELAN, PFE, GB:AZN, RHHBY, LLY, MRK and 16 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.